Diabetes Technology & TherapeuticsVol. 11, No. 2 EDITORIALCGM—A Technology in EvolutionJay S. SkylerJay S. SkylerSearch for more papers by this authorPublished Online:16 Jan 2009https://doi.org/10.1089/dia.2008.0140AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail "CGM—A Technology in Evolution." , 11(2), pp. 63–64FiguresReferencesRelatedDetailsCited ByNewer Modalities in the Treatment of Type 2 Diabetes Mellitus: Focus on Technology21 February 2019Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital23 June 2018 | Diabetes Care, Vol. 41, No. 8Factory-Calibrated Continuous Glucose Sensors: The Science Behind the Technology Udo Hoss and Erwin Satrya Budiman1 May 2017 | Diabetes Technology & Therapeutics, Vol. 19, No. S2Newer devices and improved formulations of inhaled insulin8 December 2014 | Expert Opinion on Drug Delivery, Vol. 12, No. 6Continuous Glucose Monitoring in Insulin-Treated Patients in Non-ICU Settings13 August 2014 | Journal of Diabetes Science and Technology, Vol. 8, No. 5Wearable and implantable pancreas substitutes20 September 2012 | Journal of Artificial Organs, Vol. 16, No. 1Neural Network Incorporating Meal Information Improves Accuracy of Short-Time Prediction of Glucose ConcentrationIEEE Transactions on Biomedical Engineering, Vol. 59, No. 6Insulin Analogs and Glycosylated Hemoglobin Target of Less Than 7% in Type 2 Diabetes: A Systematic Review of Randomized Trials Katherine Esposito, Maria Ida Maiorino, Giuseppe Bellastella, Paolo Chiodini, and Dario Giugliano25 May 2011 | Metabolic Syndrome and Related Disorders, Vol. 9, No. 3Can technological solutions for diabetes replace islet cell function?27 October 2014 | Organogenesis, Vol. 7, No. 1Pulmonary Formulations: What Remains to be Done? Jeffry G. Weers, John Bell, Hak-Kim Chan, David Cipolla, Craig Dunbar, Anthony J. Hickey, and Ian J. Smith6 December 2010 | Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 23, No. S2Initiation of Prandial Insulin Therapy with AIR Inhaled Insulin or Insulin Lispro in Patients with Type 2 Diabetes: A Randomized Noninferiority Trial Jorge L. Gross, Masako Nakano, Gildred Colon-Vega, Ramon Ortiz-Carasquillo, Jeffrey A. Ferguson, Sandra Althouse, Janet A. Tobian, Pierre-Yves Berclaz, and Zvonko Milicevic22 September 2009 | Diabetes Technology & Therapeutics, Vol. 11, No. s2Safety and Efficacy of AIR Inhaled Insulin Compared with Subcutaneous Insulin in Patients Having Diabetes and Asthma: A 12-Month, Randomized, Noninferiority Trial Ernesto Ang, Mary K. Lawrence, Cory R. Heilmann, Jeffrey A. Ferguson, Janet A. Tobian, David M. Webb, and Pierre-Yves Berclaz22 September 2009 | Diabetes Technology & Therapeutics, Vol. 11, No. s2Insulin Delivery via Lungs—Is It Still Possible? Satish K. Garg and William C. Kelly22 September 2009 | Diabetes Technology & Therapeutics, Vol. 11, No. s2The Future of Continuous Glucose Monitoring Satish K. Garg26 May 2009 | Diabetes Technology & Therapeutics, Vol. 11, No. S1Continuous Glucose Monitoring: An Overview of Its Development Jay S. Skyler26 May 2009 | Diabetes Technology & Therapeutics, Vol. 11, No. S1BENEFITS OF THREE-MONTH CONTINUOUS GLUCOSE MONITORING FOR PERSONS WITH DIABETES USING INSULIN PUMPS AND SENSORSBiomedical Papers, Vol. 153, No. 1 Volume 11Issue 2Feb 2009 Information© 2009 Mary Ann Liebert, Inc.To cite this article:Jay S. Skyler.CGM—A Technology in Evolution.Diabetes Technology & Therapeutics.Feb 2009.63-64.http://doi.org/10.1089/dia.2008.0140Published in Volume: 11 Issue 2: January 16, 2009PDF download
Read full abstract